Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31672759 | 0.72 | KMT2A (0.41) | NOS2NOS3KDM4EALDH1A1CYP1A2 | |
| SCHEMBL10553433 | 0.72 | NOS2 (0.46) | NOS2NOS3NOS1BACE1KDM4E | |
| SCHEMBL10863598 | 0.70 | NOS2 (0.57) | NOS2NOS3NOS1BACE1KDM4E | |
| SCHEMBL3452701 | 0.69 | ALDH1A1 (0.35) | KDM4EALDH1A1POLBCYP1A2MAPK1 | |
| Hydrochloric Acid SCHEMBL3060195 | 0.68 | NOS3 (0.40) | NOS2NOS3NOS1ALDH1A1 | |
| SCHEMBL3062694 | 0.68 | HSP90AA1 (0.43) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL7284590 | 0.67 | NOS3 (0.42) | NOS2NOS3 | |
| SCHEMBL9218265 | 0.67 | NOS3 (0.42) | NOS2NOS3KDM4EALDH1A1CYP1A2 | |
| SCHEMBL9495660 | 0.67 | NOS3 (0.42) | NOS2NOS3 | |
| SCHEMBL10730571 | 0.66 | NOS3 (0.47) | NOS2NOS3NOS1BACE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368342-B3 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-7642267-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2008-09-18 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2006-02-02 | — | — | US | disclosed |
| EP-1368342-B1 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6916819-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | NOS2 4108/4885NOS3 3877/4885NOS1 4528/4885 |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | NOS2 4108/4885NOS3 3877/4885NOS1 4528/4885 |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABBR2, GABRA2 | NOS2 4108/4885NOS3 3877/4885NOS1 4528/4885 |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABRA1, GABBR2 | NOS2 4220/4885NOS3 3972/4885NOS1 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.